Case series supporting heme detoxification via therapeutic plasma exchange in acute multiorgan failure syndrome resistant to red blood cell exchange in sickle cell disease

Transfusion

Volumn 58, Issue 2, 2018, Pages 470-479

  Louie, James E ^a   Anderson, Caitlin J ^b   Fayaz M Fomani, Katayoun ^a   Henry, Alonye ^b   Killeen, Trevor ^c   Mohandas, Narla ^b   Yazdanbakhsh, Karina ^b   Belcher, John D ^c   Vercellotti, Gregory M ^c   Shi, Patricia A ^b  

^a Northwell Health   (United States)

^b NEW YORK BLOOD CENTER   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; HAPTOGLOBIN; HEME; HEMOPEXIN;

ADULT; ARTICLE; BLOOD STORAGE; CASE REPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DISEASE RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE TRANSFUSION; EXCHANGE BLOOD TRANSFUSION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PLASMA EXCHANGE; PROTEIN BLOOD LEVEL; REFRIGERATION; SICKLE CELL ANEMIA; THAWING; YOUNG ADULT; BLOOD; METABOLISM; PLASMA;

ADULT; ERYTHROCYTE TRANSFUSION; FEMALE; HEME; HUMANS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PLASMA; PLASMA EXCHANGE;

EID: 85041412240     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14407     Document Type: Article

References (84)

1. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood 2012;120:3647-56.
2. Ballas SK, Marcolina MJ. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion 2006;46:105-10.
3. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002;8:1383-9.
4. Belcher JD, Chen C, Nguyen J, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood 2014;123:377-90.
5. Ghosh S, Adisa OA, Chappa P, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest 2013;123:4809-20.
6. Chen G, Zhang D, Fuchs TA, et al. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood 2014;123:3818-27.
7. Camus SM, Gausserès B, Bonnin P, et al. Erythrocyte microparticles can induce kidney vaso-occlusions in a murine model of sickle cell disease. Blood 2012;120:5050-58.
8. Sparkenbaugh EM, Chantrathammachart P, Wang S, et al. Excess of heme induces tissue factor-dependent activation of coagulation in mice. Haematologica 2015;100:308-14.
9. Schimmel M, Nur E, Biemond BJ, et al. Nucleosomes and neutrophil activation in sickle cell disease painful crisis. Haematologica 2013;98:1797-803.
10. Setty BN, Key NS, Rao AK, et al. Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis. Br J Haematol 2012;157:370-80.
11. van Beers E, Yang Y, Raghavachari N, et al. Iron, inflammation, and early death in adults with sickle cell disease. Circ Res 2014;116:296-306.
12. Chen J, Hobbs WE, Le J, et al. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood 2011;117:3680-3.
13. Hagger D, Wolff S, Owen J, et al. Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinolysis 1995;6:93-9.
14. Detterich JA, Kato RM, Rabai M, et al. Chronic transfusion therapy improves but does not normalize systemic and pulmonary vasculopathy in sickle cell disease. Blood 2015;126:703-10.
15. Vinchi F, Costa da Silva M, Ingoglia G, et al. Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease. Blood 2016;127:473-86.
16. Loomis Z, Eigenberger P, Redinius K, et al. Hemoglobin induced cell trauma indirectly influences endothelial TLR9 activity resulting in pulmonary vascular smooth muscle cell activation. PLoS One 2017;12:e0171219.
17. Schaer DJ, Buehler PW. Cell-free hemoglobin and its scavenger proteins: new disease models leading the way to targeted therapies. Cold Spring Harb Perspect Med 2013;3.
18. Dutra FF, Alves LS, Rodrigues D, et al. Hemolysis-induced lethality involves inflammasome activation by heme. Proc Natl Acad Sci USA 2014;111:E4110-8.
19. Gladwin MT. Revisiting the hyperhemolysis paradigm. Blood 2015;126:695.
20. Schaer DJ, Buehler PW, Alayash AI, et al. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013;121:1276-84.
21. Schaer DJ, Vinchi F, Ingoglia G, et al. Haptoglobin, hemopexin, and related defense pathways-basic science, clinical perspectives, and drug development. Front Physiol 2014;5:415.
22. Nagababu E, Fabry ME, Nagel RL, et al. Heme degradation and oxidative stress in murine models for hemoglobinopathies: thalassemia, sickle cell disease and hemoglobin C disease. Blood Cells Mol Dis 2008;41:60-6.
23. Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest 2017;127:750-60.
24. Adisa OA, Hu Y, Ghosh S, et al. Association between plasma free haem and incidence of vaso-occlusive episodes and acute chest syndrome in children with sickle cell disease. Br J Haematol 2013;162:702-5.
25. Saraf SL, Zhang X, Kanias T, et al. Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. Br J Haematol 2014;164:729-39.
26. Schein A, Enriquez C, Coates TD, et al. Magnetic resonance detection of kidney iron deposition in sickle cell disease: a marker of chronic hemolysis. J Magn Reson Imaging 2008;28:698-704.
27. Saraf SL, Zhang X, Shah B, et al. Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy. Haematologica 2015;100:1275-84.
28. Eshbach ML, Kaur A, Rbaibi Y, et al. Hemoglobin inhibits albumin uptake by proximal tubule cells: implications for sickle cell disease. Am J Physiol Cell Physiol 2017;312:C733-40.
29. Thomsen JH, Etzerodt A, Svendsen P, et al. The haptoglobin-CD163-heme oxygenase-1 pathway for hemoglobin scavenging. Oxid Med Cell Longev 2013;2013:523652.
30. Lim SK, Kim H, Lim SK, et al. Increased susceptibility in Hp knockout mice during acute hemolysis. Blood 1998;92:1870-7.
31. Tolosano E, Fagoonee S, Hirsch E, et al. Enhanced splenomegaly and severe liver inflammation in haptoglobin/hemopexin double-null mice after acute hemolysis. Blood 2002;100:4201-8.
32. Schaer CA, Deuel JW, Schildknecht D, et al. Haptoglobin preserves vascular nitric oxide signaling during hemolysis. Am J Respir Crit Care Med 2016;193:1111-22.
33. Baek JH, D'Agnillo F, Vallelian F, et al. Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. J Clin Invest 2012;122:1444-58.
34. Shibasaki T, Matsuda H, Furuya K. Haptoglobin therapy during pregnancy for paroxysmal nocturnal hemoglobinuria with renal failure. Int J Gynaecol Obstet 2007;98:267-8.
35. Vinchi F, Gastaldi S, Silengo L, et al. Hemopexin prevents endothelial damage and liver congestion in a mouse model of heme overload. Am J Pathol 2008;173:289-99.
36. Vinchi F, De Franceschi L, Ghigo A, et al. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation 2013;127:1317-29.
37. Shi PA, Choi E, Chintagari NR, et al. Sustained treatment of sickle cell mice with haptoglobin increases HO-1 and H-ferritin expression and decreases iron deposition in the kidney without improvement in kidney function. Br J Haematol 2016;175:714-23.
38. Vercellotti GM, Zhang P, Nguyen J, et al. Hepatic overexpression of hemopexin inhibits inflammation and vascular stasis in murine models of sickle cell disease. Mol Med 2016;22:437-51.
39. Lezcano NE, Odo N, Kutlar A, et al. Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke 2006;37:1424-6.
40. Naumann HN, Diggs LW, Barreras L, et al. Plasma hemoglobin and hemoglobin fractions in sickle cell crisis. Am J Clin Pathol 1971;56:137-47.
41. Bourantas KL, Dalekos GN, Makis A, et al. Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol 1998;61:49-54.
42. Muller-Eberhard U, Javid J, Liem HH, et al. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood 1968;32:811-5.
43. Santiago RP, Figueiredo CV, Fiuza LM, et al. Serum haptoglobin and hemopexin levels in pediatric SS and SC disease patients: biomarker of hemolysis and inflammation. Blood 2016;128:3649.
44. Nielsen MJ, Moller HJ, Moestrup SK. Hemoglobin and heme scavenger receptors. Antioxid Redox Signal 2010;12:261-73.
45. Foidart M, Liem HH, Adornato BT, et al. Hemopexin metabolism in patients with altered serum levels. J Lab Clin Med 1983;102:838-46.
46. Noyes WD, Garby L. Rate of haptoglobin in synthesis in normal man. Determinations by the return to normal levels following hemoglobin infusion. Scand J Clin Lab Invest 1967;20:33-8.
47. Hassell KL, Eckman JR, Lane PA. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. Am J Med 1994;96:155-62.
48. Chaturvedi S, Ghafuri DL, Glassberg J, et al. Rapidly progressive acute chest syndrome in individuals with sickle cell anemia: a distinct acute chest syndrome phenotype. Am J Hematol 2016;91:1185-90.
49. Henriksen LO, Faber NR, Moller MF, et al. Stability of 35 biochemical and immunological routine tests after 10 hours storage and transport of human whole blood at 21°C. Scand J Clin Lab Invest 2014;74:603-10.
50. Jansen EH, Beekhof PK, Schenk E. Long-term stability of biomarkers of the iron status in human serum and plasma. Biomarkers 2013;18:365-8.
51. Shinowara GY. Spectrophotometric studies on blood serum and plasma; the physical determination of hemoglobin and bilirubin. Am J Clin Pathol 1954;24:696-710.
52. Oh JY, Hamm J, Xu X, et al. Absorbance and redox based approaches for measuring free heme and free hemoglobin in biological matrices. Redox Biol 2016;9:167-77.
53. Gislefoss RE, Grimsrud TK, Morkrid L. Long-term stability of serum components in the Janus Serum Bank. Scand J Clin Lab Invest 2008;68:402-9.
54. Kellogg RM, Hester JP. Kinetics modeling of plasma exchange: intra- and post-plasma exchange. J Clin Apher 1988;4:183-7.
55. Cid J, Elena M, Diekmann F, et al. Haptoglobin is present in albumin used as a replacement solution for plasma exchange. Transfusion 2013;53:757-60.
56. Smith H, Owen JA. The determination of haptoglobins in normal human serum. Biochem J 1961;78:723-8.
57. Hanstein A, Muller-Eberhard U. Concentration of serum hemopexin in healthy children and adults and in those with a variety of hematological disorders. Lab Clin Med 1968;71:232-9.
58. Gardner K, Thein SL. Super-elevated LDH and thrombocytopenia are markers of a severe subtype of vaso-occlusive crisis in sickle cell disease. Am J Hematol 2015;90:E206-7.
59. Ballas SK, Bauserman RL, McCarthy WF, et al. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. J Pain Symptom Manage 2010;40:870-82.
60. Aneke JC, Huntley N, Porter J, et al. Effect of automated red cell exchanges on oxygen saturation on-air, blood parameters and length of hospitalization in sickle cell disease patients with acute chest syndrome. Niger Med J 2016;57:190-3.
61. Shome DK, Ramadorai P, Al-Ajmi A, et al. Thrombotic microangiopathy in sickle cell disease crisis. Ann Hematol 2013;92:509-15.
62. Boga C, Kozanoglu I, Ozdogu H, et al. Plasma exchange in critically ill patients with sickle cell disease. Transfus Apher Sci 2007;37:17-22.
63. Bolanos-Meade J, Keung YK, Lopez-Arvizu C, et al. Thrombotic thrombocytopenic purpura in a patient with sickle cell crisis. Ann Hematol 1999;78:558-9.
64. Chehal A, Taher A, Shamseddine A. Sicklemia with multi-organ failure syndrome and thrombotic thrombocytopenic purpura. Hemoglobin 2002;26:345-51.
65. Geigel EJ, Francis CW. Reversal of multiorgan system dysfunction in sickle cell disease with plasma exchange. Acta Anaesthesiol Scand 1997;41:647-50.
66. Svarch E, Gonzalez A, Villaescusa R, et al. Plasma exchange for acute cholestasis in homozygous sickle cell disease. Haematologia (Budap) 1986;19:49-51.
67. Stankovic Stojanovic K, Steichen O, Lefevre G, et al. High lactate dehydrogenase levels at admission for painful vaso-occlusive crisis is associated with severe outcome in adult SCD patients. Clin Biochem 2012;45:1578-82.
68. Huehns ER, Davies SC, Brozovic M. Fresh frozen plasma for vaso-occlusive crises in sickle cell disease. Lancet 1981;1:1310-1.
69. Neisser-Svae A, Trawnicek L, Heger A, et al. Five-day stability of thawed plasma: solvent/detergent-treated plasma comparable with fresh-frozen plasma and plasma frozen within 24 hours. Transfusion 2016;56:404-9.
70. Dengler T, Stocker U, Kellner S, et al. Chemical and immunochemical characterization of polymers of aggregates in preparations of human serum albumin. Infusionstherapie 1989;16:160-4.
71. Deuel JW, Vallelian F, Schaer CA, et al. Different target specificities of haptoglobin and hemopexin define a sequential protection system against vascular hemoglobin toxicity. Free Radic Biol Med 2015;89:931-43.
72. Smith A, Morgan WT. Haem transport to the liver by haemopexin. Receptor-mediated uptake with recycling of the protein. Biochem J 1979;182:47-54.
73. Ramji DP, Cortese R, Cilberto G. Regulation of C-reactive protein, haptoglobin, and hemopexin gene expression. In: Mackiewicz A, Kushner I, Baumann H, editors. Acute phase proteins molecular biology, biochemistry, and clinical applications. Boca Raton (FL): CRC Press, 1993.
74. Bertolini J, Hayes T. Plasma for fractionation. In: Bertolini J, Hayes T, editors. Production of plasma proteins for therapeutic use. New York: Wiley; 2012. p. 423-36.
75. Hvidberg V, Maniecki MB, Jacobsen C, et al. Identification of the receptor scavenging hemopexin-heme complexes. Blood 2005;106:2572-9.
76. Boretti FS, Baek JH, Palmer AF, et al. Modeling hemoglobin and hemoglobin:haptoglobin complex clearance in a non-rodent species-pharmacokinetic and therapeutic implications. Front Physiol 2014;5:385.
77. Tokola O, Tenhunen R, Volin L, et al. Pharmacokinetics of intravenously administered haem arginate. Br J Clin Pharmacol 1986;22:331-5.
78. Camus SM, De Moraes JA, Bonnin P, et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood 2015;125:3805-14.
79. Zhou Z, Han H, Cruz MA, et al. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost 2009;101:1070-7.
80. Novelli EM, Kato GJ, Hildesheim ME, et al. Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease. Haematologica 2013;98:e132-4.
81. Sins JW, Schimmel M, Luken BM, et al. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state. J Thromb Haemost 2017;15:1392-402.
82. Godefroy E, Liu Y, Shi P, et al. Altered heme-mediated modulation of dendritic cell function in sickle cell alloimmunization. Haematologica 2016;101:1028-38.
83. Zhong H, Bao W, Friedman D, et al. Hemin controls T cell polarization in sickle cell alloimmunization. J Immunol 2014;193:102-10.
84. Ballas SK. From total blood exchange to erythrocytapheresis and back to treat complications of sickle cell disease. Transfusion 2017;57:2277-80.